AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01057797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: upper body strength training
Description: 16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
Study NCT03197194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
Study NCT03197194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: one tablet of aspirin 300 mg
Study NCT03197194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
Study NCT03197194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo IV
Description: IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
Study NCT02086409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with vitamin D and calcium
Description: The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
Study NCT02086409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt not supplemented with vitamin D and calcium
Description: The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
Study NCT01160094 — intervention group
Intervention type: DRUG
Intervention: Treatment
Description: patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
Study NCT01848509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With teletransmission
Description: Teletransmission of alerts
Study NCT01126008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT with weekly docetaxel & cisplatin
Description: radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
Study NCT03114657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT03114657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT00673426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodic
Study NCT02698644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoamyl-2-cyanoacrylate
Description: Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
Study NCT02598011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
Study NCT02598011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Study NCT02979080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eisensulfat LOMAPHARM 50 mg
Description: Eisensulfat LOMAPHARM 50 mg administration for 120 days
Study NCT03790605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % curcumin chip
Description: CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
Study NCT03790605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chip
Description: PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
Study NCT03790605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
Study NCT03790605 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
Study NCT05416645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with GERD after LSG
Description: patients with GERD after LSG
Study NCT01359618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo comparator
Description: Single dose, oral encapsulated tablet
Study NCT01729728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol oral solution single dose (1mg/kg body weight)
Study NCT02397486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Study NCT02397486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Study NCT02397486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02397486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02397486 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study NCT02525536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 3 mg/kg
Description: Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
Study NCT02525536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 10 mg/kg
Description: Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
Study NCT02525536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib 30 mg/kg
Description: Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
Study NCT00985426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
Study NCT00985426 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
Study NCT00985426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo(saline) intramuscular (IM) injection at Week 8
Study NCT05191589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic
Description: Trainees are randomized in this group to use the haptic device.
Study NCT01330056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FOPS
Description: * Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group.
Study NCT01330056 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: * Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT
Study NCT02237560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cybercycle-Game
Description: Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
Study NCT02237560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cybercyle-Tour
Description: Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
Study NCT02237560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game Only
Description: While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
Study NCT01743118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPS4251 Ointment
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Study NCT01743118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Study NCT01743118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex® ointment
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
Study NCT03233594 — intervention group
Intervention type: OTHER
Intervention: Chiropractic Group
Description: Participants will receive approximately 8 weeks of chiropractic care.
Study NCT03233594 — intervention group
Intervention type: OTHER
Intervention: Healthy Control Group
Description: Participants will not receive any interventions.
Study NCT02397486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT03947359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 M probe
Description: Measurement of liver stiffness
Study NCT03947359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan Touch 502 S probe
Description: Measurement of liver stiffness
Study NCT03062098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Ultrasound imaging during embryo transfer using a small vaginal probe.
Study NCT03883698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
Study NCT03883698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
Study NCT03883698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir 60 mg
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
Study NCT03883698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
Study NCT03635840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Aortic Balloon Pump
Description: Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand.
Study NCT02143310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVP
Study NCT02673554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP Bolus
Description: bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
Study NCT02673554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP Clamp
Description: hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
Study NCT04480567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 307
Description: AAV Gene Therapy Infusion
Study NCT02673554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Description: an oral glucose challenge (75 g)
Study NCT02673554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp
Description: a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
Study NCT02971228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
Study NCT02971228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207 (dasiglucagon)
Description: A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
Study NCT02971228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
Study NCT02971228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPhone-based bionic pancreas
Description: An experimental device.
Study NCT02971228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet-based bionic pancreas
Description: An experimental device.
Study NCT01721083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Z-track
Description: Subject received immunization by z-track
Study NCT01721083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Bunch
Description: Subject receives immunization by bunch method.
Study NCT04270747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 938
Description: Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Study NCT04270747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABP 938
Description: Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Study NCT04270747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Study NCT03675412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine tablet
Description: Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
Study NCT02482935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT03961997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 50 mg
Description: Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
Study NCT03961997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 75 mg
Description: Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
Study NCT03961997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib 100 mg
Description: Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
Study NCT03330717 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Patients will undergo oncologic breast surgery on general anesthesia.
Study NCT03330717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis sedation
Description: Patients will undergo oncologic breast surgery on hypnosis sedation.
Study NCT03330717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with preoperative session of hypnosis
Description: Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Every 3 weeks
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Every 3 weeks
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Every 3 weeks
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Every 3 weeks
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Every 3 weeks
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Every week
Study NCT03264547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administered for 2 weeks and is then stopped to be administered for 1 week
Study NCT02146092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Study NCT02146092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Standard of care exercise training and supervision
Study NCT02146092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Standard of care exercise training and supervision
Study NCT04131010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single operator video cholangioscopy
Description: The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
Study NCT04295018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study NCT00757978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: memantine 10mg twice a day
Study NCT00757978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo twice a day
Study NCT02969629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Study NCT02969629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT00255944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youthnet Internet-based program
Description: Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
Study NCT00255944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Internet based program
Description: The control program will deliver standard STD/HIV prevention messages.
Study NCT04052932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1
Description: tablets，dose1，QD
Study NCT04052932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose2
Description: tablets，dose2，QD
Study NCT04052932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: tablets，QD
Study NCT04052932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: tablets，300mg，QD
Study NCT01129115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonexercise control group
Description: Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
Study NCT01129115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group 1
Description: The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
Study NCT04226495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Infusion
Description: Intra-operative sufentanil infusion
Study NCT04226495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Bolus
Description: Intra-operative sufentanil bolus